This article was originally published in The Tan Sheet
FDA issues call for data on antidiarrheal ingredient Saccharomyces boulardii 250 mg in capsule form taken one to two times daily, according to a notice slated for publication in the Federal Register Aug. 23. The agency "has reviewed a time and extent application for this condition and determined that it is eligible for consideration in its OTC drug monograph system." The notice adds that either an official or proposed U.S. Pharmacopoeia-National Formulary monograph must be submitted as part of the review because one was not included as part of the TEA...
You may also be interested in...
FDA withdraws its 2004 notice of eligibility and request for information to aid its consideration of adding Saccharomyces boulardii to the antidiarrheal OTC drug product monograph. FDA determined the yeast is best regulated as a biological product, the agency said in an Oct. 27 notice in the Federal Register (1"The Tan Sheet" Aug. 23, 2004, In Brief)
An EU guideline on the methodological aspects of pharmacoepidemiology has been updated to promote collaboration by researchers on high-quality, multi-centre observational studies in the context of COVID-19.
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.